«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

26卷

期数:

2020年06期

页码:

538-541

栏目:

临床医学

出版日期:

2020-11-20

文章信息/Info

Title:

Detection and significance of plasma sIL-2R and MUC1 in patients with ulcerative colitis

作者:

谭莉霞; 仝甲钊; 王航宇; 董勇; 华静; 魏书堂; 杨文义

河南大学第一附属医院消化内科，开封 475000

Author(s):

TAN Li-xia;  TONG Jia-zhao;  WANG Hang-yu;  DONG Yong;  HUA Jing;  WEI Shu-tang;  YANG Wen-yi

Department of Gastroenterology, The First Affiliated Hospital of Henan University, Kaifeng 475000, China

关键词:

溃疡性结肠炎; 可溶性白细胞介素-2受体; 上皮细胞膜结合黏液素1

Keywords:

ulcerative colitis;  soluble interleukin-2 receptor;  epithelial membrane-bound mucin-1;  prognosis

分类号:

R574.62

DOI:

-

文献标志码:

A

摘要:

目的：分析溃疡性结肠炎患者血浆可溶性白细胞介素-2受体（sIL-2R）、上皮细胞膜结合黏液素1（MUC1）检测的意义。方法：检测溃疡性结肠炎患者（研究组）及体检健康者（对照组）血浆sIL-2R、MUC1水平。对比分析研究组轻、中、重度及活动期、缓解期患者各指标水平，另外比较活动期预后良好与预后不良患者各指标水平，采用受试者工作特征（ROC）曲线评估血浆sIL-2R、MUC1水平检测对活动期患者预后的预测价值。结果：研究组sIL-2R、MUC1水平[（354.71±11.26）、（11.93±2.38）U/mL]高于对照组[（91.65±8.32）、（6.84±1.52）U/mL]（t=158.329、15.038，均P=0.000），研究组活动期sIL-2R、MUC1水平[（390.72±11.63）、（14.85±3.06）U/mL]高于缓解期[（287.34±9.25）、（6.47±1.04）U/mL]（t=42.754、14.765，均P=0.000），研究组预后良好者sIL-2R、MUC1水平[（365.71±10.48）、（13.43±2.16）U/mL]低于预后不良者[（477.29±11.73）、（19.77±1.94）U/mL]（t=32.933、9.521，均P=0.000），sIL-2R、MUC1水平在轻、中、重度患者中依次升高（F=627.902、67.224，均P＜0.05）；二者单项及联合检测的灵敏度76.92%、84.62%、76.92%，特异度80.00%、77.78%、86.67%。结论：溃疡性结肠炎患者血浆sIL-2R、MUC1水平升高，与病情程度、活动性相关，可预测预后。

Abstract:

Objective: To analyze the significance of detection of plasma soluble interleukin-2 receptor(sIL-2R) and membrane-bound mucin-1 of epithelial cells(MUC1) levels in patients with ulcerative colitis. Methods: The levels of sIL-2R and MUC1 in ulcerative colitis patients(study group) and healthy people(control group) were measured. The indicators of mild, moderate and severe patients of study group and in active and remission patients were compared and analyzed, and the levels of indexes between the patients with good prognosis and the patients with poor prognosis in the active period were compared, then the prediction values of sIL-2R and MUC1 levels in the prognosis of patients with active stage were evaluated by receiver operator characteristic(ROC) curve. Results: The levels of sIL-2R and MUC1 in study group [(354.71 ± 11.26), (11.93 ± 2.38) U/mL] were higher than those in control group[(91.65±8.32), (6.84±1.52) U/mL] (t = 158.329, 15.038, all P = 0.000), and the levels of sIL-2R and MUC1 in active phase of study group [(390.72±11.63), (14.85±3.06) U/mL ] were higher than those in remission stage[(287.34±9.25),(6.47±1.04) U/mL] (t = 42.754, 14.765, all P = 0.000), and levels of sIL-2R and MUC1 in the good prognosis patients of study group [(365.71±10.48), (13.43±2.16) U/mL]were lower than those in the poor prognosis patients [(477.29±11.73)，(19.77±1.94) U/mL ](t=32.933, 9.521, all P = 0.000),and the levels of sIL-2R and MUC1 in mild, moderate and severe patients were increased in turn(F=627.902,67.224, all P< 0.05). The sensitivity of the two indexes single and combined detection in predicting the prognosis were 76.92%, 84.62%, 76.92% and the specificity were 80.00%, 77.78%, 86.67%. Conclusion: The plasma levels of sIL-2R and MUC1 in patients with ulcerative colitis are high, which are related to the severity and activity of the disease, and can predict the prognosis.

参考文献/References:

[1] Sugiyama T，Sasaki M，Nakagawa S，et al. The association among enterobacterial flora， dietary factors， and prognosis in patients with ulcerative colitis[J]. J Clin Biochem Nutr，2020，66（2）：152
[2] Tatiya-Aphiradee N，Chatuphonprasert W，Jarukamjorn K. Immune response and inflammatory pathway of ulcerative colitis[J]. J Basic Clin Physiol Pharmacol，2018，30（1）：1
[3] Sharma P，Poojary G，Dwivedi S N，et al. Effect of Yoga-based intervention in patients with inflammatory bowel disease[J].Int J Yoga Therap，2015，25（1）：101
[4] Kvorjak M，Ahmed Y，Miller M L，et al. Cross-talk between colon cells and macrophages increases ST6GALNAC1 and MUC1-sTn expression in ulcerative colitis and colitis-associated colon cancer[J].Cancer Immunol Res，2020，8（2）：167
[5] 林三仁. 消化内科诊疗常规[M].北京：中国医药科技出版社，2012：35-36
[6] 中国中西医结合学会消化系统疾病专业委员会.溃疡性结肠炎中西医结合诊疗指南（草案）[J].中国中西医结合消化杂志，2011， 19（1）：61
[7] 张天生. 溃疡性结肠炎[M].北京：中国医药科技出版社，2012：21-22
[8] 袁柏新.溃疡性结肠炎内镜下评分与临床及实验室炎症指标相关性研究[J].重庆医学，2018，47（15）：2042
[9] Okada T，Kanda T，Ueda N，et al. IL-8 and LYPD8 expression levels are associated with the inflammatory response in the colon of patients with ulcerative colitis[J]. Biomed Rep，2020，12（4）：193
[10] Ochsenkühn T，Tillack C，Szokodi D，et al. Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis[J]. United European Gastroenterol J，2020，8（1）：91
[11] Smids C，Horjus Talabur Horje C S，Nierkens S，et al. Candidate serum markers in early crohn′s disease：predictors of disease course[J]. J Crohns Colitis，2017，11（9）：1090
[12] 沈浩.溃疡性结肠炎患者免疫功能状态的临床研究[J].现代消化及介入诊疗，2016，21（4）：554
[13] 邓磊，何松，赵晓莉.溃疡性结肠炎和结直肠癌患者血清MUC1的表达水平及临床意义[J].现代医药卫生，2018，34（23）：3631
[14]刘别影.中药灌肠对溃疡性结肠炎患者血清细胞因子sIL-2R、CIC的影响[J].海南医学院学报，2013，19（9）：1267
[15] Hosomi S，Yamagami H，Itani S，et al. Sepsis markers soluble IL-2 receptor and soluble CD14 subtype as potential biomarkers for complete mucosal healing in patients with inflammatory bowel disease[J]. J Crohns Colitis，2018，12（1）：87
[16] Hofmann S R，Kubasch A S，Range U，et al. Serum biomarkers for the diagnosis and monitoring of chronic recurrent multifocal osteomyelitis （CRMO）[J].Rheumatol Int，2016，36（6）：769
[17] Vancamelbeke M，Vanuytsel T，Farré R，et al. Genetic and transcriptomicbases of intestinal epithelial barrier dysfunction in inflammatory bowel disease[J].Inflamm Bowel Dis，2017，23（10）：1718
[18] Khemiri M，Doghri R，Mrad K，et al. Mucin-1 expression andlocalization in epithelial cells shows characteristic and distinct patterns in inflammatory bowel diseases and colorectal cancer[J]. Int J Clin Exp Pathol，2019，12（5）：1731

相似文献/References:

备注/Memo

备注/Memo:

文章编号 1006-8147（2020）06-0538-04
基金项目 开封市科技发展计划项目（1903099）
作者简介 谭莉霞（1988-），女，主治医师，硕士，研究方向：消化道肿瘤； 通信作者：杨文义，E-mail： Yangwenyihgz@163.com。

常用功能

更新日期/Last Update: 2020-11-20